News headlines about Oxford Immunotec Global PLC (NASDAQ:OXFD) have trended somewhat positive on Friday, according to AlphaOne Sentiment. AlphaOne, a division of Accern, identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oxford Immunotec Global PLC earned a news impact score of 0.15 on AlphaOne’s scale. AlphaOne also gave press coverage about the company an impact score of 10 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Alpha One Sentiment’s analysis:
- Oxford Immunotec Global PLC (OXFD) VP Elizabeth M. Keiley Sells 4,085 Shares (americanbankingnews.com)
- Zacks: Oxford Immunotec Global PLC (OXFD) Given Consensus Rating of “Strong Buy” by Analysts (americanbankingnews.com)
- ETFs with exposure to Oxford Immunotec Global Plc : June 15, 2017 (finance.yahoo.com)
- Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation (finance.yahoo.com)
- Oxford Immunotec Global Plc breached its 50 day moving average in a Bullish Manner : OXFD-US : June 16, 2017 (finance.yahoo.com)
Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Oxford Immunotec Global PLC from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Thursday, March 9th. BTIG Research reaffirmed a “buy” rating and set a $19.00 price target on shares of Oxford Immunotec Global PLC in a research note on Friday, March 10th. Finally, ValuEngine raised shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Oxford Immunotec Global PLC has a consensus rating of “Hold” and a consensus target price of $18.00.
Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 0.79% during midday trading on Friday, reaching $15.01. 109,375 shares of the company traded hands. The firm has a 50 day moving average of $14.48 and a 200-day moving average of $14.57. The stock’s market capitalization is $344.12 million. Oxford Immunotec Global PLC has a 12 month low of $7.73 and a 12 month high of $16.13.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. Oxford Immunotec Global PLC had a negative net margin of 25.83% and a negative return on equity of 31.48%. The company had revenue of $21.51 million during the quarter, compared to the consensus estimate of $21.17 million. Analysts forecast that Oxford Immunotec Global PLC will post ($1.09) EPS for the current fiscal year.
In other Oxford Immunotec Global PLC news, VP Elizabeth M. Keiley sold 4,085 shares of the stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $15.01, for a total value of $61,315.85. Following the completion of the sale, the vice president now directly owns 25,393 shares of the company’s stock, valued at approximately $381,148.93. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Elizabeth M. Keiley sold 3,000 shares of the stock in a transaction on Monday, March 20th. The shares were sold at an average price of $16.05, for a total transaction of $48,150.00. Following the completion of the sale, the vice president now directly owns 25,429 shares of the company’s stock, valued at $408,135.45. The disclosure for this sale can be found here. Over the last three months, insiders sold 93,085 shares of company stock valued at $1,374,176. Insiders own 7.58% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Extremely Unlikely to Impact Oxford Immunotec Global PLC (OXFD) Stock Price” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.wkrb13.com/markets/2229259/somewhat-favorable-press-coverage-extremely-unlikely-to-impact-oxford-immunotec-global-plc-oxfd-stock-price.html.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229259/somewhat-favorable-press-coverage-extremely-unlikely-to-impact-oxford-immunotec-global-plc-oxfd-stock-price.html
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.